4896 K Pharma,Inc. - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

4896

TSE Growth

K Pharma,Inc.

583

JPY

-31

(-5.05%)

Dec 23, 3:30 pm JST

3.72

USD

Dec 23, 1:30 am EST

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2020 Changed ＊	ー	ー	-269	-271	-38.8	0	ー	J-GAAP
Dec, 2021 ＊	ー	-219	-220	-228	-30.1	0	ー	J-GAAP
Dec, 2022 ＊	ー	-353	-359	-392	-42.1	0	ー	J-GAAP
Dec, 2023	1,000	366	344	260	25.4	0	Feb 14, 2024	J-GAAP
Dec, 2024 Guidance	ー	-1,043	-1,043	-1,057	-91.1	0	Feb 14, 2024	J-GAAP
YoY	－	－	－	－	－

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2023	Oct 17, 2023	1,000	302	266	180	0*	J-GAAP
Results	Feb 14, 2024	1,000	366	344	260	0*	J-GAAP
Dec, 2024	Feb 14, 2024	ー	-1,043	-1,043	-1,057	0	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Oct, 2018	ー	－	Available in future release
Oct, 2019	ー	－
Dec, 2020 Changed	ー	－
Dec, 2021	ー	－
Dec, 2022	ー	－
Dec, 2023	1,000	－
Dec, 2024 Guidance	ー	-100.0	-1,043	－	-1,043	－	-91.1	－

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2023	1,000	366	36.6	11.71	11.09	0.43	25.4
Dec, 2024 Guidance	ー	-1,043	ー	-42.62	-40.69	ー	-91.1

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	1,000	366	344	260	25.4
Fiscal Year	Dec, 2023	Dec, 2023	Dec, 2023	Dec, 2023	Dec, 2023

Second Half

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jul - Dec, 2023	0	-285	-307	-254	-24.8	0	Feb 14, 2024	J-GAAP
Jul - Dec, 2024 Guidance	ー	-620	-621	-631	-54.4	0	Aug 14, 2024	J-GAAP
YoY	－	-117.5%	-102.3%	-148.4%	-119.0%

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2021	-219	-196	-196	0	368	188	91.71	J-GAAP
Dec, 2022	-353	-395	-363	-32	1,544	1,336	97.23	J-GAAP
Dec, 2023	366	443	454	-11	1,486	3,266	98.58	J-GAAP

Actual Performance and Financial Trends

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Jan - Sep, 2023	1,000	515	508	398	40.3	147.7	Nov 13, 2023	J-GAAP
Jan - Sep, 2024	0	-620	-619	-624	-53.8	ー	Nov 14, 2024	J-GAAP
YoY	－	－	－	－	－

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2023	500	332	332	248	25.2	66.4	ー	J-GAAP
Apr - Jun, 2023	500	319	319	266	27.0	63.8	ー	J-GAAP
Jul - Sep, 2023	0	-136	-143	-116	-11.8	-Inf	Nov 13, 2023	J-GAAP
Oct - Dec, 2023	0	-149	-164	-138	-13.5	-Inf	Feb 14, 2024	J-GAAP
Jan - Mar, 2024	0	-230	-230	-233	-20.1	-Inf	May 13, 2024	J-GAAP
Apr - Jun, 2024	0	-193	-192	-193	-16.7	-Inf	Aug 14, 2024	J-GAAP
Jul - Sep, 2024	0	-197	-197	-198	-17.1	-Inf	Nov 14, 2024	J-GAAP
YoY	－	-44.9%	-37.8%	-70.7%	-45.3%

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2023	500	－	Available in future release
Apr - Jun, 2023	500	－
Jul - Sep, 2023	0	－
Oct - Dec, 2023	0	－
Jan - Mar, 2024	0	-100.0
Apr - Jun, 2024	0	-100.0
Jul - Sep, 2024	0	－	-197	-44.9	-197	-37.8	-17.1	-44.9

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	500	332	332	266	27.0
Fiscal Year	Mar, 2023	Mar, 2023	Mar, 2023	Jun, 2023	Jun, 2023

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Interest-Bearing Debt Ratio	Announce	Accounting Standards
Dec, 2021	-107,030.00	86.8	205	178	ー	ー	ー	J-GAAP
Dec, 2022	-122,770.00	97.2	1,374	1,336	-1,012	ー	ー	J-GAAP
Dec, 2023	267.55	93.7	3,313	3,104	-752	ー	Feb 14, 2024	J-GAAP
Jan - Sep, 2024	ー	95.5	2,598	2,480	-624	ー	Nov 14, 2024	J-GAAP

K Pharma,Inc.(4896) Financial Results